US FDA approves Syndax's blood cancer drug
Portfolio Pulse from
The U.S. FDA has approved Syndax Pharmaceuticals' drug for treating a type of blood cancer in both adults and children, leading to a 3% increase in the company's shares during after-hours trading.
November 15, 2024 | 11:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Syndax Pharmaceuticals received FDA approval for its blood cancer drug, which led to a 3% increase in its stock price during after-hours trading.
The FDA approval is a significant milestone for Syndax Pharmaceuticals, as it allows the company to market its drug for blood cancer treatment. This regulatory approval is likely to boost investor confidence and positively impact the stock price in the short term, as evidenced by the 3% increase in after-hours trading.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100